Alnylam Pharmaceuticals (ALNY), an RNAi therapeutics company, has signed a huge license with Roche which could be worth as much as $1 billion The small company had total revenue fo $26 million last year.
Under the terms of the agreeement: "Alnylam will give Roche a non-exclusive license to its technology. Roche will pay $331 million in upfront fees, including making an investment of just under 2 million shares of Alnylam stock, representing nearly 5 percent of the company’s outstanding shares," according to the AP.
Shares in ALNY are up 52% to $23.30, which takes the company’s market cap to $875 million.
The stock still looks cheap.
Douglas A. McIntyre
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
